Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.06 USD
Change Today +0.0035 / 6.09%
Volume 1.6M
ISCO On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/28/14 - $0.20
52 Week Low
07/9/14 - $0.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

international stem cell corp (ISCO) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCO) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCO) Details

International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and biomedical products worldwide. Its products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. The company develops cell types, such as neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat congenital and acquired liver diseases; islet cells for the treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. It also offers cosmetic skin care products through professional channels and distributors, as well as through a branded Website; and human cell culture products for use in pharmaceutical, academic, and government research organizations. The company’s human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines to study breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company offers its human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 02/6/15
Founded in 2001

international stem cell corp (ISCO) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $246.1K
Executive Vice President of Business Developm...
Total Annual Compensation: $220.0K
Chief Scientific Officer and Director
Total Annual Compensation: $196.9K
Compensation as of Fiscal Year 2014.

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Receives Key Stem Cell Patent in Japan

International Stem Cell Corporation announced that the Japan Patent Office has granted ISCO's patent covering methods of making a bank of human stem cells from parthenogenetically activated eggs, significantly strengthening the company's intellectual property position and partnering ability in Japan. ISCO's patent covers a new method of creating stem cells that combine many of the benefits of embryonic stem cells with induced pluripotent stem cells and can be used to generate virtually unlimited quantities of human cells. The company is currently using this technology to develop treatments for a number of indications where cell therapy has been demonstrated to be effective but there is insufficient supply of safe, functional cells. Preclinical safety and efficacy data from the company's Parkinson's disease program was recently presented at the Society for Neuroscience annual meeting, and a Phase I/IIa clinical study in Parkinson's disease is anticipated to begin in the near future.

International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial

International Stem Cell Corporation announced that the company has completed manufacturing of the cell bank of clinical-grade human neural stem cells using its patented process for the recently announced phase 1/2a clinical trial in Parkinson's disease. The cell bank contains over 2.6 billion human cells, sufficient to meet the company's foreseeable clinical trial requirements. ISCO's master cell bank of human parthenogenetic neural stem cells (ISC-hpNSC) is produced in compliance with current good manufacturing practices (cGMPs) and the chemistry and manufacturing controls (CMC) discussed in the previously reported pre-IND meeting with the FDA. The cells are karyotypically normal hpNSCs and free of measurable contaminants of human or animal origin. The production of hpNSCs from undifferentiated pluripotent human parthenogenetic stem cells in the master cell bank uses qualified reagents and a standardized protocol developed by ISCO. The undifferentiated human stem cells are derived from the parthenogenetic line and were recently cleared by the FDA for use in clinical trials. Each batch of hpNSC is subjected to standardized quality control testing to ensure viability, sterility and appropriate cellular composition before clinical use. The existing master cell bank and current production scale are sufficient to supply anticipated product needs through pivotal clinical trials. The cell bank was produced at the company's GMP manufacturing facility located in Oceanside, Calif. ISC-hpNSCs are a novel therapeutic cellular product derived from the Company's proprietary human pluripotent stem cells. Neural stem cells are self-renewing multipotent cells that are precursors for the main cell types of the central nervous system. The ability of ISC-hpNSCs to differentiate into dopaminergic neurons and express brain-protecting neurotrophic factors offers a new opportunity for the treatment of Parkinson's disease. ISCO's preclinical program includes animal studies to assess the safety and tolerability of novel cell therapy as well as doses ranging efficacy to be used to design the first clinical trial in Parkinson's disease patients.

International Stem Cell to Launch Start the Phase 1/2a Clinical Study of its Cell Therapy

International Stem Cell announced that it intends to start the phase 1/2a clinical study of its cell therapy for the treatment of Parkinson's disease in Australia within the next few months. The company has completed the required preclinical studies for the phase 1/2a clinical study of the clinical product, ISC-hpNSC, for the treatment of Parkinson's disease. This TGA submission includes non-clinical studies evaluating the safety and tolerability of the clinical product, ISC-hpNSC, in different animal species, including non-human primates, along with the chemistry and manufacturing controls and a summary of the clinical study design, according to the company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $0.06 USD +0.0035

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.01 USD -0.0001
Cytori Therapeutics Inc $1.19 USD +0.01
Nuo Therapeutics Inc $0.26 USD +0.017
ReNeuron Group PLC 3.63 GBp 0.00
StemCells Inc $0.99 USD +0.013
View Industry Companies

Industry Analysis


Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at